Friday, 16 October 2026European Markets

SCHEERD.V KERCHOVE Stock Over 17% Down So Far On Tuesday

Loading stream...

(VIANEWS) - Shares of SCHEERD.V KERCHOVE (BEL 20: SCHD.BR) slid by a staggering 17.29% to €488.00 at 14:21 EST on Tuesday, following the last session's upward trend. BEL 20 is falling 1.26% to €3,702.66, after three successive sessions in a row of gains. This seems, up until now, an all-around down trend trading session today.

SCHEERD.V KERCHOVE's last close was €550.00, 14.06% under its 52-week high of €640.00.

About SCHEERD.V KERCHOVE

Scheerders van Kerchove's Verenigde fabrieken nv manufactures and distributes building materials. It offers façade panels, slates, facing bricks, and corrugated sheets. The company was founded in 1905 and is based in Sint-Niklaas, Belgium.

Earnings Per Share

As for profitability, SCHEERD.V KERCHOVE has a trailing twelve months EPS of €-3.3.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -15.06%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 4.1%, now sitting on 39.97M for the twelve trailing months.

More news about SCHEERD.V KERCHOVE (SCHD.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com